Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat 3 Stocks Under $5 With Strong Analyst Upside PotentialAuthor: Chris Markoch. Published: 2/24/2026. 
Key Points - Grab Holdings is gaining analyst support as revenue growth and its first full year of profitability highlight long-term opportunity in Southeast Asia’s expanding digital economy.
- Vaxart offers speculative biotech upside with its oral vaccine platform targeting influenza, norovirus, and COVID-19, creating a high-risk, high-reward setup.
- ThredUp is positioned to benefit from the fast-growing resale market, with strong institutional ownership and industry forecasts pointing to sustained secondhand demand.
- Special Report: [Sponsorship-Ad-6-Format3]
While many investors are rotating out of speculative penny stocks, others still embrace the risk-reward dynamic. Stocks trading under $5 come with inherent risk: many of these companies are unprofitable, and some generate little or no revenue. In almost every case, these are small-cap companies. Small caps have been beaten up over the last several years, and even though the Russell 2000 is showing some signs of life, that strength hasn't been widespread across the small-cap universe. I Met Elon Musk "Face-to-Face"
During a private gathering of Wall Street elites, I was one of two people selected to speak with Elon personally.
As a result, my research now leads me to believe Elon will announce the SpaceX IPO on this date:
March 26, 2026. Circle it on your calendar.
I'm sharing an "access code" that lets anyone grab a pre-IPO stake before it happens. This is your invitation to the biggest wealth-building event of the decade. Click Here to See how to Get Your "SpaceX Access Code" That could change in 2026 if the economic outlook continues to improve. In that scenario, capital may flow back into speculative names—but, as always, quality matters. One way to screen for quality is to look for names with positive analyst sentiment. These three stocks fit that criterion. Each lets investors start a sizable position with a modest outlay while retaining the potential for significant upside over the next five years. Profitability Milestone Meets Long-Term Emerging Market Growth Emerging-market stocks are expected to be winners in 2026, even though that hasn't yet been the case for Grab Holdings Inc. (NASDAQ: GRAB), which is down about 15% year-to-date. Based in Singapore, Grab operates a super app that combines technology, e-commerce and fintech services. One reason behind the stock's recent pullback is its proposed merger with Indonesian ride-hailing rival GoTo. The deal is not final and is subject to potential regulatory changes in Indonesia that could limit the company's earnings potential in that market. The company also came slightly light on the top line in its Q4 2025 earnings report. Some context is important: revenue rose 19% year-over-year, and the period marked the company's first full year of profitability. Analysts forecast roughly 120% earnings growth over the next 12 months. That helps explain why sentiment remains constructive. GRAB has a consensus price target of $6.47, which would imply about 54% upside from current levels. High-Risk Biotech With Platform Potential Penny-stock investors often look to the biotechnology sector to balance risk and reward. One name to watch is Vaxart Inc. (OTCMKTS: VXRT), the only company on this list that fits the classic penny-stock definition. At the time of writing it traded at just over $0.60 per share. VXRT doesn't have heavy analyst coverage, but the one analyst who rated it in the past 12 months put a Buy on the stock with a $2 price target. It's not uncommon for analysts to overlook some biotech firms. Vaxart is a clinical-stage company, meaning all of its candidates are still in clinical trials. The potential upside is straightforward: the company is developing oral vaccines for influenza, norovirus and COVID-19. Beyond the convenience of a pill versus an injection, Vaxart says its platform may induce a broader immune response that could offer wider protection. Institutional ownership is modest at about 18%, but in terms of dollar volume inflows have outpaced outflows nearly 10:1. Resale Tailwinds Could Turn Today's Losses Into Tomorrow's Gains ThredUp Inc. (NASDAQ: TDUP) is down roughly 33% so far in 2026, but a broader look is informative: TDUP is up more than 66% over the past 12 months, suggesting the recent decline may simply be a pullback as investors shy away from unprofitable names. With ThredUp, however, it's worth adding the caveat "yet." The company runs an online consignment and thrift marketplace that has resonated with Gen Z shoppers, as reflected in its revenue trends. In its most recent quarter, revenue rose 12.5% year-over-year. ThredUp cites a GlobalData 2025 market survey forecasting the U.S. secondhand market's gross merchandise value to grow at a compound annual growth rate of 9% through 2029. Institutional investors own an impressive 89% of TDUP, and buying has outpaced selling by about two-to-one in dollar terms and roughly three-to-one by the number of buyers versus sellers. That said, short interest sits near 17%, which can add short-term volatility. The consensus price target from six analysts is $12.50, implying more than 190% upside from current levels.
| 
